Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 9/20 | 0.47 |
| ▸ | CA2 | P00918 | 9/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8951933 | 1.00 | TSHR (0.48) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7528649 | 1.00 | TSHR (0.48) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL4278638 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL11289015 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL788634 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7030562 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL319584 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL4704343 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7198908 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL38256 | 0.99 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933288-B2 | Pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2005-08-23 | — | — | US | disclosed |
| US-6933288-B2 | Pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2005-08-23 | — | — | US | disclosed |
| US-20030216575-A1 | Novel pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | disclosed |
| US-20030216575-A1 | Novel pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003066633-A1 | NOVEL PYRANOSYL CYTOSINES: PHARMACEUTICAL FORMULATIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066633-A1 | NOVEL PYRANOSYL CYTOSINES: PHARMACEUTICAL FORMULATIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216575-A1 | Novel pyranosyl cytosines: pharmaceutical formulations and methods | RNGTT, NOP2, RNMT | TSHR 4596/4885CA1 4734/4885CA2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.